第 1 章
1. World Health, O., WHO report on cancer: Setting priorities, investing wisely and providing care for all. World Health Organization: Geneva, 2020.
2. Fitzmaurice, C., Akinyemiju, T.F., Al Lami, F.H. et al. “Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study.” JAMA Oncol. 2018; 4: 1553-1568.
3. 公益財団法人 がん研究振興財団 「がんの統計ʼ19」（2019）
4. 国立がん研究センターがん情報サービス「がん登録・統計」.
5. 日本乳癌学会 「乳癌診療ガイドライン 治療編 2018 年版」, 金原出版
6. Greenberg PA, Hortobagyi GN, Smith TL., et al. “Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.” J Clin Oncol. 1996; 14: 2197-2205.
7. 日本乳癌学会 「乳腺腫瘍学 第 3 版」（2020）, 金原出版
8. Hortobagyi GN. “Treatment of breast cancer.” N Engl J Med. 1998; 339:974-984.
9. 吉川敏⼀. 「フリーラジカルの医学」京府医大誌 2011;120: 381-391
10. 吉川敏⼀, 河野雅弘, 野原⼀子「活性酸素・フリーラジカルのすべて」 (2000)；丸善出版, p.13
11. 中村成夫. 「活性酸素と抗酸化物質の化学」日医大医会誌 2013; 9: 164-169
12. 青柳⼀正. 「活性酸素」日本内科学会雑誌 1991; 80: 122-126
13. Giorgio M, Migliaccio E, Orsini F, et al. “Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis.” Cell 2005; 122: 221-33
14. Toren Finkel. “Signal transduction by reactive oxygen species.” J. Cell Biol.2011; 194: 7-15
15. Gerald W Dorn II. “Mitochondrial dynamism and heart disease: changing shape and shaping change.” EMBO Mol Med. 2015; 7: 865-877
16. 江頭享, 高山房子.「フリーラジカルと酸化ストレス-ESR による測定法を中心に-」日薬理誌（Folia Pharmacol. Jpn.）2002; 120, 229-236
17. 吉川敏⼀ 「酸化ストレスの医学」(2008); 診断と治療社
18. Buettner GR. “Spin trapping: ESR parameters of spin adducts.” Free Radic Biol Med. 1987; 3: 259-303.
19. Nakagawa H, Ohyama R, Kimata A, et al. “Hydroxyl radical scavenging by edaravone derivatives: Efficient scavenging by 3-methyl-1-(pyridin-2-yl)-5- pyrazolone with an intramolecular base.” Bioorg Med Chem Lett. 2006; 16: 5939-42.
20. Matsumoto C, Sekine-Suzuki E, Nyui M, et al. “Analysis of the antioxidative function of the radioprotective Japanese traditional (Kampo) medicine, hangeshashinto, in an aqueous phase.” J Radiat Res. 2015; 56: 669-77.
21. Althoff F, Benzing K, Comba P, et al. “Abiotic methanogenesis from organosulphur compounds under ambient conditions.” Nat Commun. 2014; 5: 4205.
22. Bonnet, S., Archer, S. L., Allalunis-Turner, J., et al. “A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth.” Cancer Cell. 2007; 11: 37-51.
23. Pallab M, Samik B, Uday B, et al. “Indomethacin, a Non-steroidal Anti- inflammatory Drug, Develops Gastropathy by Inducing Reactive Oxygen Species-mediated Mitochondrial Pathology and Associated Apoptosis in Gastric Mucosa.” J Biol Chem. 2009; 284: 3058-3068
24. Deeley, R. G., Westlake, C., Cole, S. P., “Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins.” Physiol Rev. 2006; 86: 849-899.
25. Gottesman, M. M. “Mechanisms of cancer drug resistance.” Annu Rev Med.2002; 53: 615-627.
26. Ambudkar, S. V., Kim, I. W., Xia, D., et al. “The A-loop, a novel conserved aromatic acid subdomain upstream of the Walker A motif in ABC transporters, is critical for ATP binding.” FEBS Lett. 2006; 580: 1049-1055.
27. Dean, M. and T. Annilo. “Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates.” Annu Rev Genomics Hum Genet 2005; 6: 123-142.
28. Doyle, L. A., Yang, W., Abruzzo, L. V., et al. “A multidrug resistance transporter from human MCF-7 breast cancer cells.” Proc Natl Acad Sci U SA. 1998; 95: 15665-15670.
29. Tiwari, A. K., Sodani, K., Dai, C. L., et al. “Revisiting the ABCs of multidrug resistance in cancer chemotherapy.” Curr Pharm Biotechnol. 2011; 12: 570- 594.
30. Wang, Y. J., Zhang, Y. K., Kathawala, R. J., et al. “Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance.” Cancers (Basel). 2014; 6: 1925-1952.
31. Takahashi, M., Furihata, M., Akimitsu, N., et al. “A highly bone marrow metastatic murine breast cancer model established through in vivo selection exhibits enhanced anchorage-independent growth and cell migration mediated by ICAM-1.” Clin Exp Metastasis. 2008; 25: 517-529.
32. Aslakson, C. J. and F. R. Miller. “Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor.” Cancer Res. 1992; 52: 1399-1405.
33. Takahashi, M., Miyazaki, H., Furihata, M., et al. “Chemokine CCL2/MCP-1 negatively regulates metastasis in a highly bone marrow-metastatic mouse breast cancer model.” Clin Exp Metastasis. 2009; 26: 817-828.
34. Cailleau, R., Olivé, M., Cruciger, Q. V., et al. “Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization.” In Vitro. 1978; 14: 911-915.
35. Siciliano, M. J., et al. “Mutually exclusive genetic signatures of human breast tumor cell lines with a common chromosomal marker.” Cancer Res. 1979; 39(3): 919-922.
36. Soule, H. D., Barker, P. E., Cailleau, R. “A human cell line from a pleural effusion derived from a breast carcinoma.” J Natl Cancer Inst. 1973; 51: 1409-1416.
37. Brooks, S. C., Locke, E. R., Soule, H. D. “Estrogen receptor in a human cell line (MCF-7) from breast carcinoma.” J Biol Chem. 1973; 248: 6251-6253.
第 2 章
1. Latest Global Cancer Data: Cancer Burden Rises to 18.1 Million New Cases and 9.6 Million Cancer Deaths in 2018, International Agency for Research on Cancer, World Health Organization.
2. Müller A, Homey B, Soto H, et al. “Involvement of chemokine receptors in breast cancer metastasis” Nature 2001; 410: 50-56.
3. Coleman RE and Rubens RD. “The clinical course of bone metastases from breast cancer” Br. J. Cancer 1987; 55: 61-66.
4. Coleman RE. “Clinical features of metastatic bone disease and risk of skeletal morbidity” Clin. Cancer Res. 2006; 12: 6243s-6249s.
5. Papapetrou PD. “Bisphosphonate-associated adverse events” Hormones 2009; 8: 96-110.
6. Agostinis P, Berg K, Cengel KA., et al “Photodynamic therapy of cancer: an update” CA Cancer J. Clin. 2011; 61: 250-281.
7. Moret F and Reddi E. “Strategies for optimizing the delivery to tumors of macrocyclic photosensitizers used in photodynamic therapy (PDT)” J. Porphyrins Phthalocyanines 2017; 21: 239-256.
8. Stummer W, Pichlmeier U, Meinel T., et al. “Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial” Lancet Oncol. 2006; 7: 392-401.
9. Hadjipanayis CG, Widhalm G and Stummer W. “What is the Surgical Benefit of Utilizing 5-Aminolevulinic Acid for Fluorescence-Guided Surgery of Malignant Gliomas?” Neurosurgery 2015; 77: 663-673.
10. Kriegmair M, Baumgartner R, Lumper W., et al. “Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer” Br. J. Urol. 1996; 77: 667-671.
11. Ito H, Tamura M, Matsui H., et al “Reactive oxygen species involved cancer cellular specific 5-aminolevulinic acid uptake in gastric epithelial cells” J. Clin. Biochem. Nutr. 2014; 54: 81-85.
12. Kurokawa H, Ito H and Matsui H. “The Cisplatin-Derived Increase of Mitochondrial Reactive Oxygen Species Enhances the Effectiveness of Photodynamic Therapy via Transporter Regulation” Cells 2019; 8: 918.
13. Nakamura S, Takamura T, Matsuzawa-Nagata N., et al. “Palmitate induces insulin resistance in H4IIEC3 hepatocytes through reactive oxygen species produced by mitochondria” J. Biol. Chem. 2009; 284: 14809-14818.
14. Reuter S, Gupta SC, Chaturvedi MM., et al. “Oxidative stress, inflammation, and cancer: how are they linked?” Free Radic. Biol. Res. 2010; 49: 1603-1616.
15. Sullivan LB and Chandel NS. “Mitochondrial reactive oxygen species and cancer” Cancer Metab. 2014; 2: 17.
16. Tamura M, Matsui H, Tomita T., et al. “Mitochondrial reactive oxygen species and cancer” J. Clin. Biochem. Nutr. 2014; 54: 12-17.
17. Hiyama K, Matsui H, Tamura M., et al. “Cancer cells uptake porphyrins via heme carrier protein 1” J. Porphyrins Phthalocyanines 2013; 17: 36-43.
18. Nagano Y, Matsui H, Shimokawa O., et al “Rebamipide attenuates nonsteroidal anti-inflammatory drugs (NSAID) induced lipid peroxidation by the manganese superoxide dismutase (MnSOD) overexpression in gastrointestinal epithelial cells” J. Physiol. Pharmacol. 2012; 63: 137-142.
19. Ito H, Matsui H, Hirayama A., et al. “Reactive oxygen species induced by non-steroidal anti-inflammatory drugs enhance the effects of photodynamic therapy in gastric cancer cells” J. Clin. Biochem. Nutr. 2016; 58: 180-185.
20. Liou GY and Storz P. “Reactive oxygen species in cancer” Free Radic. Res.2010; 44: 479-496.
21. Birben E, Sahiner UM, Sackesen C., et al. “Oxidative stress and antioxidant defense” World Allergy Organ J. 2012; 5: 9-19.
22. Hagiya Y, Endo Y, Yonemura Y, et al. “Pivotal roles of peptide transporter PEPT1 and ATP-binding cassette (ABC) transporter ABCG2 in 5- aminolevulinic acid (ALA)-based photocytotoxicity of gastric cancer cells in vitro” Photodiagn. Photodyn. Ther. 2012; 9: 201-214.
23. Kurokawa H, Ito H, Terasaki M., et al. “Hyperthermia enhances photodynamic therapy by regulation of HCP1 and ABCG2 expressions via high level ROS generation” Sci. Rep. 2019; 9: 1638.
24. Doyle LA, Yang W, Abruzzo LV., et al. “A multidrug resistance transporter from human MCF-7 breast cancer cells” Proc. Natl. Acad. Sci. USA 1998; 95: 15665-15670.
25. Doyle L and Ross DD. “Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)” Oncogene 2003; 22: 7340-7358.
26. Yamamoto F, Ohgari Y, Yamaki N., et al. “The role of nitric oxide in delta- aminolevulinic acid (ALA)-induced photosensitivity of cancerous cells” Biochem. Biophys. Res. Commun. 2007; 353: 541-546.
27. Zhen J, Lu H, Wang XQ., et al. “Upregulation of endothelial and inducible nitric oxide synthase expression by reactive oxygen species” Am. J. Hypertens. 2008; 21: 28-34.
28. Motoori S, Majima HJ, Ebara M., et al. “Overexpression of mitochondrial manganese superoxide dismutase protects against radiation-induced cell death in the human hepatocellular carcinoma cell line HLE” Cancer Res. 2001; 61: 5382‒5388.
29. Furukawa T, Kohno H, Tokunaga R., et al “Nitric oxide-mediated inactivation of mammalian ferrochelatase in vivo and in vitro: possible involvement of the ironsulphur cluster of the enzyme” Biochem. J. 1995; 310: 533‒538.
30. Takahashi M, Furihata M, Akimitsu N., et al “A highly bone marrow metastatic murine breast cancer model established through in vivo selection exhibits enhanced anchorage-independent growth and cell migration mediated by ICAM-1” Clin. Exp. Metastasis 2008; 25: 517‒529.
31. Takahashi M, Miyazaki H, Furihata M., et al “Chemokine CCL2/MCP-1 negatively regulates metastasis in a highly bone marrow-metastatic mouse breast cancer model” Clin. Exp. Metastasis 2009; 26: 817‒828.
第 3 章
1. 日本ハイパーサーミア学会（2008）「ハイパーサーミア がん温熱療法ガイドブック」毎日健康サロン
2. Ohguri, T. “Current Status of Clinical Evidence for Electromagnetic Hyperthermia on Prospective Trials.” Thermal Medicine 2015; 31: 5-12.
3. Wust, P., et al. “Hyperthermia in combined treatment of cancer.” The Lancet Oncology 2002; 3: 487-497.
4. Bull, J. M. “An update on the anticancer effects of a combination of chemotherapy and hyperthermia.” Cancer Res. 1984; 44: 4853s-4856s.
5. Schildkopf, P., Ott, O. J., Frey, B., et al. “Biological rationales and clinical applications of temperature controlled hyperthermia--implications for multimodal cancer treatments.” Curr Med Chem. 2010; 17: 3045-3057.
6. Frey, B., Weiss, E. M., Rubner, Y., et al. “Old and new facts about hyperthermia-induced modulations of the immune system.” Int J Hyperthermia 2012; 28: 528-542.
7. Kurokawa, H., Ito, H., Matsui, H., “The Cisplatin-Derived Increase of Mitochondrial Reactive Oxygen Species Enhances the Effectiveness of Photodynamic Therapy via Transporter Regulation.” Cells 2019; 8: 918.
8. Kurokawa, H., Ito, H., Terasaki, M., et al. “Hyperthermia enhances photodynamic therapy by regulation of HCP1 and ABCG2 expressions via high level ROS generation.” Sci Rep. 2019; 9: 1638.
9. Doyle, L. A., Yang, W., Abruzzo, L. V., et al. “A multidrug resistance transporter from human MCF-7 breast cancer cells.” Proc Natl Acad Sci U SA 1998; 95: 15665-15670.
10. Ejendal, K. F. and C. A. Hrycyna. “Multidrug resistance and cancer: the role of the human ABC transporter ABCG2.” Curr Protein Pept Sci. 2002; 3: 503- 511.
11. Zhao, G., Yu, R., Deng, J., et al. “Pivotal Role of Reactive Oxygen Species in Differential Regulation of Lipopolysaccharide-Induced Prostaglandins Production in Macrophages.” Molecular Pharmacology 2013; 83: 167.
12. Curtin, J. F., Donovan, M., Cotter, T. G., “Regulation and measurement of oxidative stress in apoptosis.” J Immunol Methods 2002; 265: 49-72.
13. Slimen, I. B., Najar, T., Ghram, A., et al. “Reactive oxygen species, heat stress and oxidative-induced mitochondrial damage. A review.” Int J Hyperthermia 2014; 30: 513-523.
14. Kalyanaraman, B., Cheng, G., Hardy, M., et al. “Teaching the basics of reactive oxygen species and their relevance to cancer biology: Mitochondrial reactive oxygen species detection, redox signaling, and targeted therapies.” Redox Biol. 2018; 15: 347-362.
15. Terasaki, M., Ito, H., Kurokawa, H., et al. “Acetic acid is an oxidative stressor in gastric cancer cells.” J Clin Biochem Nutr. 2018; 63: 36-41.
16. Tamura, M., Matsui, H., Tomita, T., et al. “Mitochondrial reactive oxygen species accelerate gastric cancer cell invasion.” Journal of Clinical Biochemistry and Nutrition 2014; 54: 12-17.
17. Dewhirst, M. W., Viglianti, B. L., Lora-Michiels, M., et al. “Basic principles of thermal dosimetry and thermal thresholds for tissue damage from hyperthermia.” Int J Hyperthermia 2003; 19: 267-294.
18. Horsman, M. R. and J. Overgaard “Hyperthermia: a potent enhancer of radiotherapy.” Clin Oncol (R Coll Radiol.) 2007; 19: 418-426.
論文の公開元へ
